Group 1 - Yihau New Materials plans to reduce its shareholding by up to 1% of the company's total shares, amounting to 165,500 shares, due to personal funding needs [1] - Fuxing Pharmaceutical's subsidiary has received approval for a new indication for its drug, which is used in the treatment of certain types of breast cancer [1][2] - Shantui Co. has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [3] Group 2 - Sierte's chairman plans to increase his shareholding by an amount between 3 million to 6 million yuan [4] - Borui Pharmaceutical's BGM0504 tablet has received approval for clinical trials in overweight and obese adults [5] - Ganyue Expressway reported vehicle toll service revenue of 349 million yuan for August [6] Group 3 - Chip Microelectronics has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [7] - Lingrui Pharmaceutical's director plans to reduce his shareholding by up to 200,000 shares, representing 0.0353% of the total shares [8] - Jiahu Energy has adjusted its share repurchase price limit to 11.63 yuan per share [10] Group 4 - Spring Airlines reported a year-on-year increase of 12.23% in passenger turnover for August [11] - Kaida has received an invention patent for a self-calibrating sensor technology [12] - Chuanheng Co. has obtained a new utility model patent aimed at improving industrial waste utilization [14] Group 5 - Huashi Technology received a government subsidy of 2.21 million yuan, accounting for 22.71% of its latest audited net profit [15] - Shanghai Pharmaceuticals' controlling shareholder plans to increase its H-share holdings by up to 74 million shares [16] - Hongrun Construction has won a bid for a significant segment of the Shanghai Metro Line 21 project, valued at 126 million yuan [18] Group 6 - Sanfangxiang plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on green technology [19] - Lao Fengxiang's subsidiaries plan to jointly invest in luxury goods sales and gold refining companies [20][21] - China Eastern Airlines reported an 8.72% year-on-year increase in passenger turnover for August [22] Group 7 - Inner Mongolia First Machinery has signed a railway freight car procurement contract worth 186 million yuan [22] - Jiuqiang Bio has received five invention patents related to diagnostic reagents [24] - Longmag Technology plans to invest 210 million yuan in its second phase project in Vietnam [25] Group 8 - Galaxy Magnetics plans to acquire 100% equity of Kyoto Longtai, with its stock suspended for trading [26] - Jinlong Co.'s controlling shareholder will have 30 million shares auctioned [27] - Haishi Co.'s controlling shareholder has released the pledge on 29.97 million shares [28] Group 9 - Qiu Tianwei plans to reduce its shareholding by up to 1.17% of the total shares [29] - Xiaocheng Technology's directors plan to reduce their shareholding by a total of 0.08% [30] - Victory Co. reported that Sunshine Life Insurance has reduced its shareholding by 4.4 million shares [31] Group 10 - Xindong Technology plans to distribute a cash dividend of 0.156 yuan per share [32] - Huaqin Technology plans to distribute a cash dividend of 0.13 yuan per share [33] - Kexing Pharmaceutical's controlling shareholder intends to transfer 5% of the company's shares [35] Group 11 - Guojin Securities has completed the repayment of its second short-term financing bond for 1.0205 billion yuan [38] - Chunhui Intelligent Control's application for asset acquisition has been accepted by the Shenzhen Stock Exchange [39] - Chaohongji has submitted its H-share issuance application to the Hong Kong Stock Exchange [40] Group 12 - Tianyue Advanced has fully exercised its over-allotment option, involving 716,180 H-shares [40] - Chengfeng Technology's vice president has resigned due to internal adjustments [41] - Yingpais plans to establish a 100 million yuan technology sports industry investment fund [43]

Group 1 - The core point of the news is that Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, received approval from the National Medical Products Administration for a new indication of the drug FCN-437c (brand name: Fuzhuoning) for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults [1] - The newly approved indication allows the drug to be used in combination with aromatase inhibitors as initial endocrine therapy [1] - The drug is an innovative small molecule CDK4/6 inhibitor with independent intellectual property rights, classified as a new structure oral medication [1] Group 2 - The drug had previously received approval for another indication for HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have progressed after prior endocrine therapy, which was approved for market entry in China by May 2025 [1] - As of August 2025, the cumulative R&D investment for this drug is approximately RMB 617 million (unaudited) [1] - According to IQVIA MIDAS™ data, global sales of CDK4/6 inhibitors are projected to be around $14.912 billion in 2024, indicating a strong market potential for the newly approved indication [2]

Core Viewpoint - Shanghai Fosun Pharmaceutical's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine injection, indicating a significant advancement in the company's product pipeline and potential market expansion [1] Group 1: Product Approval - The approved drug, Famotidine injection, is a self-developed chemical medication by the group [1] - The indication for the drug is for treating upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1] Group 2: Research and Development Investment - As of August 2025, the group has invested approximately RMB 7.67 million (unaudited) in the research and development of this drug [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine Injection, which is developed in-house and targets upper gastrointestinal bleeding caused by various factors excluding tumors and esophageal or gastric variceal bleeding [1][2]. Group 1: Product Approval - The approval of Famotidine Injection enhances the company's product portfolio [1]. - The drug is specifically indicated for upper gastrointestinal bleeding due to peptic ulcers and other causes [1]. Group 2: Financial Investment and Market Potential - The company has invested approximately RMB 7.67 million in the research and development of this drug as of August 2025 [2]. - The projected sales revenue for Famotidine Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is estimated to be around RMB 1.377 billion in 2024 [2].

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine Injection, which is developed in-house and targets upper gastrointestinal bleeding caused by various factors excluding tumors and esophageal or gastric variceal bleeding [1][3]. Group 1 - The approved indication for Famotidine Injection is for upper gastrointestinal bleeding due to peptic ulcers and other causes, excluding tumors and esophageal or gastric variceal bleeding [1]. - The total R&D investment for this drug by the company is approximately RMB 7.67 million (unaudited) as of August 2025 [2]. - The projected sales revenue for Famotidine Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 1.377 billion for the year 2024, according to IQVIA CHPA data [2]. Group 2 - The approval of this drug will further enrich the company's product line [3].

Core Insights - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, received approval from the National Medical Products Administration for a new indication of the drug FCN-437c (brand name: Fuzhuoning) for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults [1][2] - The drug is an innovative small molecule CDK4/6 inhibitor with independent intellectual property rights, classified as a major new drug creation project in China since 2018 [1] - The cumulative R&D investment for this drug reached approximately RMB 617 million (unaudited) as of August 2025 [1] Market Impact - The approval of the new indication is expected to enhance the market competitiveness of the drug and provide more treatment options for breast cancer patients in China [2] - Global sales of CDK4/6 inhibitors are projected to be approximately $14.912 billion in 2024 [2]

Core Insights - Shanghai Fosun Pharmaceutical announced that its subsidiary, Jinzhou Aohong Pharmaceutical, received approval from the National Medical Products Administration for a new indication of the drug FCN-437c (brand name: Fuzhuoning) for use in HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults [1] - The drug is an innovative small molecule CDK4/6 inhibitor with independent intellectual property rights, classified as a new structure oral medication, and was included in the national "Major New Drug Creation" technology major project in 2018 [1] - The cumulative R&D investment for this drug is approximately RMB 617 million (unaudited) as of August 2025 [1] Industry Insights - According to IQVIA MIDAS data, global sales of CDK4/6 inhibitors are projected to reach approximately $14.912 billion in 2024 [2]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for a new indication for the drug citric acid vorinostat capsules, aimed at treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in adult patients [1] Group 1 - The newly approved indication is for use in combination with aromatase inhibitors as initial endocrine therapy [1]

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上海復星醫藥（集團）股份有限公司 董事長 （於中華人民共和國註冊成立的股份有限公司） 陳玉卿 （股份代號：02196） 中國，上海 2025 年9 月1 5 日 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品獲註冊批准的公告》，僅供參閱。 承董事會命 上海复星医药（集团）股份有限公司 关于控股子公司药品获注册批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 中國，上海 2025 年9 月1 5 日 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品獲註冊批准的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * ...